“Lenvima suggests a new option for radioiodine-refractory thyroid cancer”
A new treatment option was added in the radioiodine-refractory local recurrent or progressive differentiated thyroid cancer treatment.
Eisai Korea(CEO Hong-byung Goh) held a press conference to celebrate the launch of Lenvima, a radioiodine-refractory local recurrent or progressive differentiat...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
